Skip to content

Section archive

Page 12 of 18

Cancer

Diet, lifestyle and cancer risk, prevention and treatment.

Keith Bible's phase II trial found Votrient shrank tumours in about 49 percent of patients with radioiodine-refractory differentiated thyroid cancer, with a 66 percent chance of lasting a year. Side effects were common and any survival benefit remains unclear.

3 min read

309 stories